Unknown

Dataset Information

0

Novel Hits for N-Myristoyltransferase Inhibition Discovered by Docking-Based Screening.


ABSTRACT: N-myristoyltransferase (NMT) inhibitors that were initially developed for treatment of parasitic protozoan infections, including sleeping sickness, malaria, and leismaniasis, have also shown great promise as treatment for oncological diseases. The successful transition of NMT inhibitors, which are currently at preclinical to early clinical stages, toward clinical approval and utilization may depend on the development and design of a diverse set of drug molecules with particular selectivity or pharmacological properties. In our study, we report that a common feature in the inhibitory mechanism of NMT is the formation of a salt bridge between a positively charged chemical group of the small molecule and the negatively charged C-terminus of an enzyme. Based on this observation, we designed a virtual screening protocol to identify novel ligands that mimic this mode of interaction. By screening over 1.1 million structures downloaded from the ZINC database, several hits were identified that displayed NMT inhibitory activity. The stability of the inhibitor-NMT complexes was evaluated by molecular dynamics simulations. The ligands from the stable complexes were tested in vitro and some of them appear to be promising leads for further optimization.

SUBMITTER: Spassov DS 

PROVIDER: S-EPMC9457982 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel Hits for N-Myristoyltransferase Inhibition Discovered by Docking-Based Screening.

Spassov Danislav S DS   Atanasova Mariyana M   Doytchinova Irini I  

Molecules (Basel, Switzerland) 20220826 17


N-myristoyltransferase (NMT) inhibitors that were initially developed for treatment of parasitic protozoan infections, including sleeping sickness, malaria, and leismaniasis, have also shown great promise as treatment for oncological diseases. The successful transition of NMT inhibitors, which are currently at preclinical to early clinical stages, toward clinical approval and utilization may depend on the development and design of a diverse set of drug molecules with particular selectivity or ph  ...[more]

Similar Datasets

| S-EPMC6010092 | biostudies-literature
| S-EPMC2762758 | biostudies-literature
| S-EPMC2966039 | biostudies-literature
| S-EPMC4427169 | biostudies-literature
| S-EPMC7127700 | biostudies-literature
| S-EPMC5323270 | biostudies-literature
| S-EPMC3401332 | biostudies-literature
| S-EPMC3119931 | biostudies-literature
| S-EPMC4722984 | biostudies-literature
| S-EPMC4356813 | biostudies-literature